These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

346 related items for PubMed ID: 36995604

  • 21. Comparative analysis of antisense oligonucleotide analogs for targeted DMD exon 46 skipping in muscle cells.
    Aartsma-Rus A, Kaman WE, Bremmer-Bout M, Janson AA, den Dunnen JT, van Ommen GJ, van Deutekom JC.
    Gene Ther; 2004 Sep; 11(18):1391-8. PubMed ID: 15229633
    [Abstract] [Full Text] [Related]

  • 22. Evaluation of Exon Skipping and Dystrophin Restoration in In Vitro Models of Duchenne Muscular Dystrophy.
    López-Martínez A, Soblechero-Martín P, Arechavala-Gomeza V.
    Methods Mol Biol; 2022 Sep; 2434():217-233. PubMed ID: 35213020
    [Abstract] [Full Text] [Related]

  • 23. A novel human muscle cell model of Duchenne muscular dystrophy created by CRISPR/Cas9 and evaluation of antisense-mediated exon skipping.
    Shimo T, Hosoki K, Nakatsuji Y, Yokota T, Obika S.
    J Hum Genet; 2018 Mar; 63(3):365-375. PubMed ID: 29339778
    [Abstract] [Full Text] [Related]

  • 24. The X-linked Becker muscular dystrophy (bmx) mouse models Becker muscular dystrophy via deletion of murine dystrophin exons 45-47.
    Heier CR, McCormack NM, Tully CB, Novak JS, Newell-Stamper BL, Russell AJ, Fiorillo AA.
    J Cachexia Sarcopenia Muscle; 2023 Apr; 14(2):940-954. PubMed ID: 36628607
    [Abstract] [Full Text] [Related]

  • 25. Exon-skipping therapy for Duchenne muscular dystrophy.
    Nakamura A, Takeda S.
    Neuropathology; 2009 Aug; 29(4):494-501. PubMed ID: 19486303
    [Abstract] [Full Text] [Related]

  • 26. Theoretic applicability of antisense-mediated exon skipping for Duchenne muscular dystrophy mutations.
    Aartsma-Rus A, Fokkema I, Verschuuren J, Ginjaar I, van Deutekom J, van Ommen GJ, den Dunnen JT.
    Hum Mutat; 2009 Mar; 30(3):293-9. PubMed ID: 19156838
    [Abstract] [Full Text] [Related]

  • 27. Molecular correction of Duchenne muscular dystrophy by splice modulation and gene editing.
    Hanson B, Wood MJA, Roberts TC.
    RNA Biol; 2021 Jul; 18(7):1048-1062. PubMed ID: 33472516
    [Abstract] [Full Text] [Related]

  • 28. Antisense oligonucleotide-mediated exon skipping for Duchenne muscular dystrophy: progress and challenges.
    Arechavala-Gomeza V, Anthony K, Morgan J, Muntoni F.
    Curr Gene Ther; 2012 Jun; 12(3):152-60. PubMed ID: 22533380
    [Abstract] [Full Text] [Related]

  • 29. Antisense PMO cocktails effectively skip dystrophin exons 45-55 in myotubes transdifferentiated from DMD patient fibroblasts.
    Lee J, Echigoya Y, Duddy W, Saito T, Aoki Y, Takeda S, Yokota T.
    PLoS One; 2018 Jun; 13(5):e0197084. PubMed ID: 29771942
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Multiexon skipping leading to an artificial DMD protein lacking amino acids from exons 45 through 55 could rescue up to 63% of patients with Duchenne muscular dystrophy.
    Béroud C, Tuffery-Giraud S, Matsuo M, Hamroun D, Humbertclaude V, Monnier N, Moizard MP, Voelckel MA, Calemard LM, Boisseau P, Blayau M, Philippe C, Cossée M, Pagès M, Rivier F, Danos O, Garcia L, Claustres M.
    Hum Mutat; 2007 Feb; 28(2):196-202. PubMed ID: 17041910
    [Abstract] [Full Text] [Related]

  • 32. Immortalized Muscle Cell Model to Test the Exon Skipping Efficacy for Duchenne Muscular Dystrophy.
    Nguyen Q, Yokota T.
    J Pers Med; 2017 Oct 16; 7(4):. PubMed ID: 29035327
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. Antisense-induced exon skipping for duplications in Duchenne muscular dystrophy.
    Aartsma-Rus A, Janson AA, van Ommen GJ, van Deutekom JC.
    BMC Med Genet; 2007 Jul 05; 8():43. PubMed ID: 17612397
    [Abstract] [Full Text] [Related]

  • 37. Wild-type mouse models to screen antisense oligonucleotides for exon-skipping efficacy in Duchenne muscular dystrophy.
    Cao L, Han G, Gu B, Yin H.
    PLoS One; 2014 Jul 05; 9(11):e111079. PubMed ID: 25365558
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 18.